Sphingosine‐1‐phosphate receptor 1 mediates elevated IL‐6 signaling to promote chronic inflammation and multitissue damage in sickle cell disease
Authors:
Open Access
- 17 January 2018
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 32 (5) , 2855-2865
Abstract
Sphingosine‐1‐phosphate (S1P) is a biolipid involved in chronic inflammation in several inflammatory disorders. Recent studies revealed that elevated S1P contributes to sickling in sickle cell disease (SCD), a devastating hemolytic, genetic disorder associated with severe chronic inflammation and tissue damage. We evaluated the effect of elevated S1P in chronic inflammation and tissue damage in SCD and underlying mechanisms. First, we demonstrated that interfering with S1P receptor signaling by FTY720, a U.S. Food and Drug Administration‐approved drug, significantly reduced systemic, local inflammation and tissue damage without antisickling effects. These findings led us to discover that S1P receptor activation leads to substantial elevated local and systemic IL‐6 levels in SCD mice. Genetic deletion of IL‐6 in SCD mice significantly reduced local and systemic inflammation, tissue damage, and kidney dysfunction. At the cellular level, we determined that elevated IL‐6 is a key cytokine functioning downstream of elevated S1P, which contributes to increased S1P receptor 1 ( S1pr1 ) gene expression in the macrophages of several tissues in SCD mice. Mechanistically, we revealed that S1P‐S1PR1 signaling reciprocally upregulated IL‐6 gene expression in primary mouse macrophages in a JAK2‐dependent manner. Altogether, we revealed that elevated S1P, coupled with macrophage S1PR1 reciprocally inducing IL‐6 expression, is a key signaling network functioning as a malicious, positive, feed‐forward loop to sustain inflammation and promote tissue damage in SCD. Our findings immediately highlight novel therapeutic possibilities.—Zhao, S., Adebiyi, M. G., Zhang, Y., Couturier, J. P., Fan, X., Zhang, H., Kellems, R. E., Lewis, D. E., Xia, Y. Sphingosine‐1‐phosphate receptor 1 mediates elevated IL‐6 signaling to promote chronic inflammation and multitissue damage in sickle cell disease. FASEB J. 32, 2855–2865 (2018). www.fasebj.orgKeywords
Funding Information
- National Institutes of Health
This publication has 41 references indexed in Scilit:
- Elevated adenosine signaling via adenosine A2B receptor induces normal and sickle erythrocyte sphingosine kinase 1 activityBlood, 2015
- Erythrocyte-derived sphingosine 1-phosphate is essential for vascular developmentJournal of Clinical Investigation, 2014
- Longterm Safety and Effectiveness of the Anti-interleukin 6 Receptor Monoclonal Antibody Tocilizumab in Patients with Systemic Juvenile Idiopathic Arthritis in JapanThe Journal of Rheumatology, 2014
- Circulating Monocytes Are Reduced by Sphingosine-1-Phosphate Receptor Modulators Independently of S1P3The Journal of Immunology, 2013
- Cytokine IL-6 secretion by trophoblasts regulated via sphingosine-1-phosphate receptor 2 involving Rho/Rho-kinase and Rac1 signaling pathwaysMolecular Human Reproduction, 2013
- Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state conditionEuropean Cytokine Network, 2013
- Detrimental effects of adenosine signaling in sickle cell diseaseNature Medicine, 2010
- Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2Nature, 2010
- Sphingosine 1-Phosphate Enhances Fcγ Receptor-Mediated Neutrophil Activation and Recruitment under Flow ConditionsThe Journal of Immunology, 2009
- Comparison between semi-automated segmentation and manual point-counting methods for quantitative analysis of histological sectionsJournal of Oral Science, 2006